🇺🇸 FDA

Intelligence · Patent portfolio

SANGAMO THERAPEUTICS Patents

Full USPTO pharma patent portfolio for SANGAMO THERAPEUTICS — grant dates, expiration, and drug cross-links.

Patents
192
Expiring ≤24m
7

Quick answer

SANGAMO THERAPEUTICS has 192 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 7 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 4

  1. US 10968261

    Methods and compositions for genome engineering

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10960085

    Modulation of liver genes

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10918668

    Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases

    Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10907175

    Isolated human cell with an inactivated glucocorticoid receptor gene

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10889834

    Methods and compositions for enhancing targeted transgene integration

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10888589

    Modulation of stem cells using zinc finger proteins

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10883119

    Methods and compositions for delivery of biologics

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10857203

    Methods and compositions for treating Huntington's disease

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10828376

    Liver-specific constructs and methods of use thereof

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10822599

    Compositions for linking DNA-binding domains and cleavage domains

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10808020

    Nuclease-mediated regulation of gene expression

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10724020

    Compositions for linking DNA-binding domains and cleavage domains

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10717993

    Methods and compositions for increased transgene expression

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10689717

    Methods and compositions for targeted single-stranded cleavage and targeted integration

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10675302

    Methods and compositions for targeted cleavage and recombination

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10646543

    Methods and compositions for treating trinucleotide repeat disorders

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10648001

    Method of treating mucopolysaccharidosis type I or II

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10639383

    Methods and compositions for engineering immunity

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10619154

    Nuclease-mediated regulation of gene expression

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10604771

    Delivery methods and compositions for nuclease-mediated genome engineering

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10563184

    Regulation of gene expression using engineered nucleases

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10538787

    Compositions for linking DNA-binding domains and cleavage domains

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10500229

    Targeted disruption of the MHC cell receptor

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10494648

    Delivery methods and compositions for nuclease-mediated genome engineering

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10471123

    Methods and compositions for treating Huntington's disease

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10450585

    Delivery methods and compositions for nuclease-mediated genome engineering

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10435677

    Genetically modified human cell with a corrected mutant sickle cell mutation

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10435441

    HTT repressors and uses thereof

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10407476

    Methods and compositions for treating hemophilia

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10369201

    Methods and compositions for treating Huntington's disease

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10370680

    Method of treating factor IX deficiency using nuclease-mediated targeted integration

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10344271

    Modified zinc finger binding proteins

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10293000

    Methods and compositions for the treatment of lysosomal storage diseases

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10265377

    Methods and compositions for treating Huntington's Disease

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10253333

    DNA-binding proteins and uses thereof

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10227610

    Methods and compositions for enhancing nuclease-mediated gene disruption

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10155011

    Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10143760

    Liver-specific constructs, factor VIII expression cassettes and methods of use thereof

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10117899

    Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10113207

    Methods and compositions for targeted single-stranded cleavage and targeted integration

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10081661

    Methods and compositions for genome engineering

    Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10072066

    Methods and compositions for treatment of a beta thalessemia

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10046028

    Methods and compositions for modulating PD1

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9982245

    Compositions for linking DNA-binding domains and cleavage domains

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9963715

    Methods and compositions for treatment of a genetic condition

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9957526

    Delivery methods and compositions for nuclease-mediated genome engineering

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9956247

    Method of treating lysosomal storage diseases

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9957501

    Nuclease-mediated regulation of gene expression

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does SANGAMO THERAPEUTICS have?

192 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do SANGAMO THERAPEUTICS patents expire?

7 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.